Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women
Authors:
- Cosette M WheelerCWCosette M Wheeler
- 1 July 2004
- Vol. 22 (21-22) , 2943-2952
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Benefits and Costs of Using HPV Testing to Screen for Cervical CancerJAMA, 2002
- Combined Colposcopy, Loop Conization, and Laser Vaporization Reduces Recurrent Abnormal Cytology and Residual Disease in Cervical DysplasiaGynecologic Oncology, 2000
- Human papillomavirus is a necessary cause of invasive cervical cancer worldwideThe Journal of Pathology, 1999
- Estimates of the Incidence and Prevalence of Sexually Transmitted Diseases in the United StatesSexually Transmitted Diseases, 1999
- Genital Warts and Their TreatmentClinical Infectious Diseases, 1999
- Epidemiology of Genital Human Papillomavirus InfectionThe American Journal of Medicine, 1997
- Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide PerspectiveJNCI: Journal of the National Cancer Institute, 1995
- Epidemiologic Evidence Showing That Human Papillomavirus Infection Causes Most Cervical Intraepithelial NeoplasiaJNCI: Journal of the National Cancer Institute, 1993
- Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particlesVirology, 1991
- Screening for Cervical CancerAnnals of Internal Medicine, 1990